TRIAL NAME Presenter NAME Article Reference.

Slides:



Advertisements
Similar presentations
Type the name of your inventor or invention here. Created by:
Advertisements

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.
Journal Club General Medicine C- 4/3/14
Meta-Analysis General Guidelines: Use this to file to prepare your EBP Rounds presentation if the best evidence to answer your clinical question is a Meta-Analysis.
A randomized controlled trial of citalopram on migraine frequency Satnam S. Nijjar, M.D. Department of Neurology, Johns Hopkins School of Medicine.
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Evidence-Based Journal Article Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department.
Evidence-Based Medicine Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department of.
Study Session Experimental Design. 1. Which of the following is true regarding the difference between an observational study and and an experiment? a)
Title of the Paper Your Name Critical Care Medicine School of Medicine University of Pittsburgh.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Type your question here. Type Answer Type your question here. Type Answer.
How To Design a Clinical Trial
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
Copenhagen University Hospital Rigshospitalet, Denmark
How to Read a Journal Article. Basics Always question: – Does this apply to my clinical practice? – Will this change how I treat patients? – How could.
Clinical Effectiveness Journal Club Template Topic: Presenter(s):
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Name of your genetic disease Add a picture and your name here.
Learning And Teaching Evidence Based Medicine: Asking And Answering a Clinical Question Christopher Bunt, MD, FAAFP Kimberly Jarzynka, MD, FAAFP.
Category Name $100100$100100$100100$ $200200$200200$200200$ $300300$300300$300300$ $400400$400400$400400$ $ Category Name.
 Exemplary Care  Cutting-edge Research  World-class Education  Title of the paper Your name Critical Care Medicine School of Medicine University of.
Angela Aziz Donnelly April 5, 2016
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Sample Journal Club Your Name Here.
How To Design a Clinical Trial
Title Investigators and sites. Clinical Trial Proposal Presentation Template for open forum at the 2017 ASM.
Role of The Physical Therapist in Critical Inquiry
Evidenced-Based Medicine
Writing a Manuscript Matt Fury.
PRESENTER NAME Waikato Cardiothoracic Unit Journal Club
Copenhagen University Hospital Rigshospitalet, Denmark
How to read a paper D. Singh-Ranger.
Design of Clinical Trials
INSERT YOUR GROUP NAME HERE
Critical Reading of Clinical Study Results
Nat. Rev. Nephrol. doi: /nrneph
PCSK9 Inhibitors Post-CVOTs
New Insights Into Neurogenic Orthostatic Hypotension
Neurogenic Orthostatic Hypotension: Expert Perspectives on Diagnosis and Treatment Strategies.
Case Study: 45-year-old Man
Examining CV Effects of Basal Insulin Therapy
New Treatments for CTEPH
انواع مطالعات توصيفي تحليلي مشاهده اي مداخله اي گزارش مورد گزارش موارد
Diagnosis General Guidelines:
Systematic reviews and meta-analysis
Taylor B Smith, MD1; James B Roy, MD2; Jason Kantor, MD2
Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.
PCSK9 Inhibitors and Cardiovascular Outcomes
What do you think this is a picture of? Use evidence for your answer.
Role of The Physical Therapist in Critical Inquiry
Observational Studies vs. Randomized Controlled Trials (RCT)
Evidence-based Medicine Curriculum
Clinical Effectiveness Journal Club Template
Factor Xa Inhibitors in PAD
T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight
PUT TITLE HERE Put Co-Author Listing Here
Program Goals Background: Anticoagulation in Patients With VTE.
Factor Xa Inhibitors in Coronary Artery Disease
The Research Question Background: Question:
An Unmet Need.
IMPACT OF PHARMACIST DELIVERED CARE IN THE COMMUNITY PHARMACY SETTING
= x 2 = = 20 4 x 5 = = 16 4 x 4 = = 18 6 x 3 = = 12 2 x 6 = 12.
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
My PAH Patient.
A response-adaptive platform trial may start by enrolling a broad patient population and randomise patients equally across a range of treatments, shown.
Authors: Sunil Verma Date posted: December 22, 2008
Your Name & Position What is your area of research? Describe here
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

TRIAL NAME Presenter NAME Article Reference

Picture of trial DEFINE the TRIAL ACRONYM

BACKGROUND Key points Points about why trial was made ADD PICTURE HERE

Clinical question WHAT IS THE CLINICAL QUESTION OF TRIAL? PICTURE

DESIGN Analysis: Where was it performed? N= ? Setting: Group 1 Group 2 Setting: Median follow-up: ? Primary outcome: __ Secondary outcomes: __

Population Inclusion Criteria Exclusion Criteria Key Points Contraindication to anticoagulation therapy Ineligible to undergo trials of ≥2 medications in either treatment strategy

Interventions Group 1 Group 2 (Placebo Control) DESCRIBE Group 2 (Placebo Control) Describe Any other key points re: interventions?

RESULTS

RESULTS

criticisms Criticism 1 Criticism 2 Criticism 3

Bottom line ONE LINER ON TAKE AWAY POINTS

Discussion questions Discussion question 1 Discussion question 2

Discussion ANSWERS Discussion question 1 Discussion question 2

BOARD-LIKE Question QUESTION What/When/Where/Who/Why_? _ 70 yo male __ PE: Labs: Imaging: (Adapted from MKSAP)

BOARD-LIKE Question QUESTION Educational Objective: _ Key Point: Point 1 Point 2 QUESTION What/When/Where/Who/Why_? _

CLINICAL PEARL Changes in guideline? How to apply to daily practice?

REFERENCES